BRAIN Group's Akribion Genomics business will prioritize the development of therapeutic applications within its CRISPR technology platform

• Mode of action suited for applications in oncology
• Significantly increased addressable market potential

10 January 2023, Zwingenberg (Germany) - BRAIN Biotech AG today announced its intent to prioritize the development of the genome-editing activities bundled under the brand name Akribion Genomics on therapeutic applications, including applications in oncology.